SINT · SINTX Technologies
The AI's read
SINTX now has evidence that its factory can produce and deliver more parts, with gross profit from the sales. The company also received cash, and rights to buy 941,000 more shares expired unused. Most sales still came from industrial work, and its medical products remain under development. Those limits matter, but the sales growth and smaller loss carry more weight in this report.